<DOC>
	<DOCNO>NCT00322322</DOCNO>
	<brief_summary>Hemodialysis cause carnitine deficiency . The deficiency carnitine induces anemia increase fragility red blood cell , muscular fatigue cardiac dysfunction . We propose evaluate benefit early administration L-carnitine hemodialysis patient . The patient include first month start chronic hemodialysis , randomize receive L-carnitine placebo followed-up one year .</brief_summary>
	<brief_title>Early Administration L-carnitine Hemodialysis Patients</brief_title>
	<detailed_description>The first aim study compare resistance index erythropoietin ( hemoglobin level / rHuerythropoietin dose ) L-carnitine versus placebo Double blind randomize study evaluate supplementation L-carnitine versus placebo patient begin chronic hemodialysis le 1 month . Primary outcome compare rHuerythropoietin resistance index define hemoglobin level / rHuEPO dose ratio L-carnitine placebo . Secondary endpoint compare acylcarnitine / carnitine ratio , number red blood cell transfusion , physical status , quality life , hypotensive episode , lipid profile , diabetes profile , albuminemia , c reactive protein . Several variable influence primary secondary endpoint include multivariate analysis ; albuminemia , c reactive protein , iron status , dialysis efficiency , protein intake , lipid intake , treatment additional vitamin ( C , B9 , B6 ) , treatment statin , treatment predialysis hypotension midodrine , antihypertensive treatment . Statistical analysis : - description cohort - comparison evaluate variable 2 treatment - ANOVA study repeat measurement inclusion month-12 Hb / rHuEPO dose compare course ratio group intention treat analysis - analysis ratio Hb / rHuEPO month month take account tempera withdrawal Following analysis intention treat per protocol analysis : - acylcarnitine / carnitine ratio ANOVA repeat data - number predialysis hypotension Chi2 test - number red blood cell transfusion Chi2 test - SF-36 physical status comparison mean - SF-36 total score comparison mean - lipid profile ANOVA repeat data - HbA1c ANOVA repeat data - variable influence primary secondary variable analyze multivariate analysis - statistical study clinical event per month</detailed_description>
	<mesh_term>Hyperthyroidism</mesh_term>
	<criteria>Patient le 1 month hemodialysis . Treated rHuEPO . Male female age 18 year old . With contraception treatment woman procreation age . Having receive understand information . Patients need rHuEPO Patients cancer disease Patients life expectancy 6 month Patients prove carnitine deficiency start hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>L-carnitine supplementation</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Anaemia</keyword>
	<keyword>Erythropoietin responsiveness</keyword>
</DOC>